• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.

作者信息

Dahlbäck B, Podack E R

出版信息

Biochemistry. 1985 Apr 23;24(9):2368-74. doi: 10.1021/bi00330a036.

DOI:10.1021/bi00330a036
PMID:2581612
Abstract

S protein, an inhibitor to the membrane attack complex of complement, was purified from human plasma. The procedure involved barium citrate adsorption and fractionation by poly(ethylene glycol) 4000 precipitation, followed by chromatography on DEAE-Sephacel, Blue Sepharose, Sephacryl S-200, and finally anti-albumin-Sepharose. Reduced glutathione was added throughout to inhibit spontaneous formation of disulfide-linked S-protein dimers. The recovery was 7%, resulting in approximately 10 mg of pure S protein from 1 L of starting plasma. S protein is a single-chain molecule; sedimentation equilibrium ultracentrifugation yielded a molecular weight of 83 000; the s020,W value was estimated to be 4.0 S. The purified protein contained a free, reactive thiol group causing spontaneous formation of disulfide-linked S-protein dimers. Alkylated and nonalkylated S proteins were equally active in inhibiting C9 polymerization, catalyzed by the C5b-8 complex. In parallel with the inhibition of C9 polymerization, nonalkylated S protein catalyzed the formation of disulfide-linked C9 dimers, presumably through disulfide interchanges.

摘要

相似文献

1
Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.
Biochemistry. 1985 Apr 23;24(9):2368-74. doi: 10.1021/bi00330a036.
2
Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.玻连蛋白介导的补体抑制作用:C5b - 7和C9不同结合位点的证据
Clin Exp Immunol. 1993 Apr;92(1):114-9. doi: 10.1111/j.1365-2249.1993.tb05956.x.
3
Physicochemical characterization of human S-protein and its function in the blood coagulation system.人S蛋白的物理化学特性及其在血液凝固系统中的功能
Biochem J. 1985 Oct 15;231(2):349-55. doi: 10.1042/bj2310349.
4
Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S.人C4b结合蛋白的纯化及其与维生素K依赖性蛋白S复合物的形成。
Biochem J. 1983 Mar 1;209(3):847-56. doi: 10.1042/bj2090847.
5
Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.人高密度脂蛋白及载脂蛋白对细胞结合的末端补体成分溶解作用的抑制
J Clin Invest. 1983 Apr;71(4):795-808. doi: 10.1172/jci110833.
6
Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.S蛋白对补体SC5b-9复合物中C9聚合的抑制作用。
Acta Pathol Microbiol Immunol Scand Suppl. 1984;284:89-96.
7
SC5b-7, SC5b-8 and SC5b-9 complexes of complement: ultrastructure and localization of the S-protein (vitronectin) within the macromolecules.补体的SC5b-7、SC5b-8和SC5b-9复合物:大分子内S蛋白(玻连蛋白)的超微结构与定位
Eur J Immunol. 1989 Jan;19(1):69-75. doi: 10.1002/eji.1830190112.
8
Complement inhibition by human vitronectin involves non-heparin binding domains.人玻连蛋白对补体的抑制作用涉及非肝素结合结构域。
Clin Exp Immunol. 1995 Jul;101(1):136-41. doi: 10.1111/j.1365-2249.1995.tb02289.x.
9
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly.补体膜攻击复合物中C9的分子组织。C5b-8组装诱导C9环状聚合。
J Exp Med. 1982 Jul 1;156(1):268-82. doi: 10.1084/jem.156.1.268.
10
Molecular composition of the terminal membrane and fluid-phase C5b-9 complexes of rabbit complement. Absence of disulphide-bonded C9 dimers in the membrane complex.兔补体终末膜及液相C5b-9复合物的分子组成。膜复合物中不存在二硫键连接的C9二聚体。
Biochem J. 1983 Mar 1;209(3):753-61. doi: 10.1042/bj2090753.

引用本文的文献

1
Terminal complement complexes with or without C9 potentiate antimicrobial activity against .具有或不具有C9的末端补体复合物增强对……的抗菌活性。
mBio. 2025 May 14;16(5):e0014125. doi: 10.1128/mbio.00141-25. Epub 2025 Mar 31.
2
Terminal complement complexes with or without C9 potentiate antimicrobial activity against .有或没有C9的末端补体复合物增强针对……的抗菌活性。
bioRxiv. 2025 Jan 16:2025.01.16.633325. doi: 10.1101/2025.01.16.633325.
3
Membrane attack complexes, endothelial cell activation, and direct allorecognition.膜攻击复合物、内皮细胞激活和直接同种异体识别。
Front Immunol. 2022 Sep 23;13:1020889. doi: 10.3389/fimmu.2022.1020889. eCollection 2022.
4
Two-Step Size-Exclusion Nanofiltration of Prothrombin Complex Concentrate Using Nanocellulose-Based Filter Paper.使用基于纳米纤维素的滤纸对凝血酶原复合物浓缩物进行两步尺寸排阻纳滤
Biomedicines. 2020 Mar 26;8(4):69. doi: 10.3390/biomedicines8040069.
5
Protection of host cells by complement regulators.补体调节蛋白对宿主细胞的保护作用。
Immunol Rev. 2016 Nov;274(1):152-171. doi: 10.1111/imr.12475.
6
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.金属影响人纤溶酶原激活物抑制剂-1 的结构和活性。I. 稳定性和蛋白酶抑制的调节。
Protein Sci. 2011 Feb;20(2):353-65. doi: 10.1002/pro.568.
7
Identification of disulfide bonds in protein proteolytic degradation products using de novo-protein unique sequence tags approach.使用从头蛋白质独特序列标签方法鉴定蛋白质蛋白水解降解产物中的二硫键。
J Proteome Res. 2010 Aug 6;9(8):4053-60. doi: 10.1021/pr1002559.
8
A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect.玻连蛋白M381T多态性增加了VHL基因缺陷患者患成血管细胞瘤的风险。
J Mol Med (Berl). 2009 Jun;87(6):613-22. doi: 10.1007/s00109-009-0456-1. Epub 2009 Mar 14.
9
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.纤溶酶原激活物抑制剂-1上与生长调节素B结构域之外的玻连蛋白结合位点的特征分析
J Biol Chem. 2008 Oct 17;283(42):28487-96. doi: 10.1074/jbc.M804257200. Epub 2008 Jul 24.
10
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.缺乏生长调节素B结构域的玻连蛋白缺失突变体表现出纤溶酶原激活物抑制剂-1结合活性。
J Biol Chem. 2008 Apr 18;283(16):10297-309. doi: 10.1074/jbc.M708017200. Epub 2008 Jan 3.